nach oben

Drug Safety

Erschienen in:

01.06.2004 | Review Article

Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?

Linking Pharmacology with Pharmacoepidemiology

verfasst von: Dr David W.J. Clark, Deborah Layton, Saad A.W. Shakir

Erschienen in: Drug Safety | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

Inhibitors of the cyclo-oxygenase (COX)-2 isoenzyme were developed with the expectation that their use would be accompanied by a reduction in adverse reactions thought to be mediated through COX-1 compared with conventional nonselective NSAIDs. However, the results of some clinical studies and other evidence have led to the hypothesis that use of COX-2 inhibitors may contribute to an increased risk of adverse thromboembolic (TE) events. In this review, we have evaluated the evidence from small-scale in vitro and in vivo pharmacological studies, clinical trials and large-scale pharmacoepidemiological studies and commented on the relationship between the pharmacological characteristics related to thromboembolic events and the clinical effects in large-scale clinical trials and pharmacoepidemiological studies.

Overall, the pharmacological evidence suggests that a prothrombotic effect of COX-2 selective inhibitors is plausible. To date, despite the results from the Vioxx Gastrointestinal Outcome Research (VIGOR) study from which the clinical concern regarding cardiovascular TE risk arose, the published data from other randomised controlled trials (RCTs), retrospective observational studies and spontaneous reporting schemes provide a conflicting body of evidence on the TE risk with COX-2 inhibitors.

Concerns that COX-2 inhibitors may be associated with prothrombotic effects remain and these need to be addressed in large scale, RCTs designed specifically to investigate the possibility of an excess of adverse cardiovascular outcomes in users of some or all selective COX-2 inhibitors, both with and without concomitant low-dose aspirin (acetylsalicylic acid). Consideration must also be given to other pathophysiological mechanisms for potential cardiovascular risk linked with inhibition of COX-2.

In view of the evidence reviewed, it is recommended that selective COX-2 inhibitors should be prescribed with caution, only in patients with conditions for which these drugs have proven efficacy and with careful monitoring of outcomes and adverse events. This is particularly important in the elderly, in patients with cardiovascular/renal disease and in patients with other risk factors that might predispose them to adverse events.

FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19(6 Suppl. 25): S31–6PubMed

Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105(14): 1620–2PubMedCrossRef

Food and Drug Administration Advisory Committee. Cardiovascular safety review of rofecoxib [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf [Accessed 2001 Sep 8]

Vane J. Towards a better aspirin. Nature 1994; 367(6460): 215–6PubMedCrossRef

Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90(24): 11693–7PubMedCrossRef

Vinals M, Martinez-Gonzalez J, Badimon JJ, et al. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (COX-2). Arterioscler Thromb Vasc Biol 1997; 17(12): 3481–8PubMedCrossRef

Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999; 274(17): 11660–6PubMedCrossRef

FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001; 107(11): 1335–7PubMedCrossRef

Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on cyclooxygenase-2 (COX-2) versus cyclooxygenase-1 (COX-1) in healthy volunteers. J Clin Pharmacol 2000; 40(10): 1109–20PubMed

10.

Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40(2): 124–32PubMedCrossRef

11.

McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96(1): 272–7PubMedCrossRef

12.

Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167(5): 2831–8PubMed

13.

Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102(8): 840–5PubMedCrossRef

14.

Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104(7): 820–5PubMedCrossRef

15.

Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296(5567): 539–41PubMedCrossRef

16.

Sperling R, Braunstein N, Melin J, et al. Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford, et al. Arthritis Rheum 2001; 44(5): 1229–30PubMedCrossRef

17.

Verma S, Raj SR, Shewchuk L, et al. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001; 104(24): 2879–82PubMedCrossRef

18.

Tuleja E, Mejza F, Cmiel A, et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Thromb Vasc Biol 2003; 23(6): 1111–5PubMedCrossRef

19.

Linder JD, Monkemuller KE, Davis JV, et al. Cyclooxygenase-2 (COX-2) inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000; 93(9): 930–2PubMed

20.

Crofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 (COX-2) inhibitors: a report of four cases. Arthritis Rheum 2000; 43(8): 1891–6PubMedCrossRef

21.

Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107(3): 405–9PubMedCrossRef

22.

Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 (COX-2) is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19(3): 646–55PubMedCrossRef

23.

Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105(14): 1650–5PubMedCrossRef

24.

Title LM, Giddens K, McInerney MM, et al. Effect of cyclooxygenase-2 (COX-2) inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003; 42(10): 1747–53PubMedCrossRef

25.

Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69(1): 180–6PubMed

26.

FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345(6): 433–42PubMedCrossRef

27.

Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56(2): 167–74PubMedCrossRef

28.

Blain H, Boileau C, Lapicque F, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical use. Br J Clin Pharmacol 2002; 53(3): 255–65PubMedCrossRef

29.

Fujii K, Konishi K, Kanno Y, et al. Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment. J Dermatol 2001; 28(5): 248–50PubMed

30.

Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor: pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290(2): 551–60PubMed

31.

Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65(3): 336–47PubMedCrossRef

32.

Range SP, Pang L, Holland E, et al. Selectivity of cyclooxygenase inhibitors in human pulmonary epithelial and smooth muscle cells. Eur Respir J 2000; 15(4): 751–6PubMedCrossRef

33.

Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296(2): 558–66PubMed

34.

Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002; 89(6A): 3D–9DPubMedCrossRef

35.

Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120(3): 594–606PubMedCrossRef

36.

Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287(1): 64–71PubMedCrossRef

37.

Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48(11): 3102–11PubMedCrossRef

38.

Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 (COX-2) inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 (COX-1) inactivation by aspirin. Proc Natl Acad Sci U S A 2001; 98(25): 14583–8PubMedCrossRef

39.

Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809–17PubMedCrossRef

40.

Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor (COX-2), rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40(12 Pt 2): 1509–15PubMed

41.

Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002; 42(9): 1027–30PubMed

42.

Verma S, Szmitko PE. Coxibs and the endothelium. J Am Coll Cardiol 2003; 42(10): 1754–6PubMedCrossRef

43.

Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126(8): 638–44PubMed

44.

Sackett DL, Straus ES, Richardson WS, et al. Guidelines. Table 7.2. Levels of evidence and grades of recommendations. Evidence- based medicine: how to practice and teach EBM. London: Churchill Livingstone, 2000: 173–7

45.

Mann RD. Prescription-event monitoring: recent progress and future horizons. Br J Clin Pharmacol 1998; 46(3): 195–201PubMedCrossRef

46.

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343(21): 1520–8PubMedCrossRef

47.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308 (6921): 81–106

48.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308 (6923): 235–46

49.

Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993; 14(7): 951–7PubMedCrossRef

50.

Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis. Drugs Aging 2001; 18(5): 369–88PubMedCrossRef

51.

Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104(19): 2280–8PubMedCrossRef

52.

Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11(4): 382–7PubMedCrossRef

53.

Garcia Rodriguez LA. The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin Exp Rheumatol 2001; 19(6 Suppl. 25): S41–4PubMed

54.

Bannwarth B, Treves R, Euller-Ziegler L, et al. Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. Drug Saf 2003; 26(1): 49–54PubMedCrossRef

55.

Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 89(2): 204–9PubMedCrossRef

56.

Weir MR, Sperling RS, Reicin A, et al. Selective cyclooxygenase- 2 (COX-2) inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146(4): 591–604PubMedCrossRef

57.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000; 284(10): 1247–55PubMedCrossRef

58.

White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89(4): 425–30PubMedCrossRef

59.

White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92(4): 411–8PubMedCrossRef

60.

Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective cyclo-oxygenase-2 (COX-2) inhibitors. JAMA 2001; 286(8): 954–9PubMedCrossRef

61.

GD Searle & Co. CLASS Advisory Committee Briefing Document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b 1_01_searle.pdf [Accessed 2001 Sep 8]

62.

Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324(7349): 1287–8PubMedCrossRef

63.

Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001; 286(19): 2398–400PubMedCrossRef

64.

Geis GS. Are selective COX 2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs (NSAIDs)? Pharmacia’s response to editorial. BMJ 2002; 325(7356): 161PubMedCrossRef

65.

Reicin AS, Black G, Chen I. Cardiovascular safety profile of rofecoxib in elderly patients with Alzheimer’s disease or cognitive impairment; a pooled analysis [abstract]. Ann Rheum Dis 2002; 61(1 Suppl. 1): 33–4

66.

Konstam MA. Matters of the heart: assessing the cardiovascular safety of new drugs. Am Heart J 2003; 146(4): 561–2PubMedCrossRef

67.

Mukherjee D, Topol EJ. Pharmaceutical advertising versus research spending: are profits more important than patients? Am Heart J 2003; 146(4): 563–4PubMedCrossRef

68.

Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162(10): 1111–5PubMedCrossRef

69.

Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162(10): 1099–104PubMedCrossRef

70.

Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162(10): 1105–10PubMedCrossRef

71.

Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108(10): 1191–5PubMedCrossRef

72.

Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47(4): 349–55PubMedCrossRef

73.

Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30(1): 36–40PubMed

74.

Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30(6): 1196–202PubMed

75.

Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001; 61(6): 833–65PubMedCrossRef

76.

Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359(9301): 118–23PubMedCrossRef

77.

Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002; 18(4): 229–36PubMedCrossRef

78.

Layton D, Riley J, Wilton LW, et al. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2002; 55: 166–74CrossRef

79.

Layton D, Wilton LW, Shakir SA. Celecoxib. PEM report No. 74. Oct 28, 2002

80.

Ray W, Stein C, Daugherty J, et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339): 1071–3PubMedCrossRef

81.

Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163(4): 481–6PubMedCrossRef

82.

Layton D, Heeley E, Hughes K, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42(11): 1342–53CrossRef

83.

Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50(1): 35–42PubMedCrossRef

84.

Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42(11): 1354–65CrossRef

85.

The relationship between selective cyclo-oxygenase-2 (COX-2) inhibitors and acute myocardial infarction [abstract 1823] [online]. American College of Rheumatology 2003 Scientific Meeting; 2003 Oct 23–28; 2003. Available from URL: http:// www.rheumatology.org/educ/sessions/index.asp?aud=mem [Accessed 2004 Jan 28]

86.

Shakir SA. PEM in the UK. In: Mann RD, Andrews E, editors. Pharmacovigilance. Chichester, UK: John Wiley & Sons, 2002: 333–44CrossRef

87.

Strom B. Study designs available for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons Ltd, 2000: 17–29CrossRef

88.

Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93–4CrossRef

89.

Waller P, Lee E. Responding to drug safety issues. Pharmacoepidemiol Drug Saf 1999; 8: 535–52PubMedCrossRef

90.

Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23(6): 533–42PubMedCrossRef

91.

Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23(9): 1478–91PubMedCrossRef

92.

Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26(3): 159–86PubMedCrossRef

93.

Vu D, Murty M, McMorran M. Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse reactions. Can Adv Reaction News 2002; 12(2): 1–3

94.

Coulter DM. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach. Drug Saf 2002; 25(6): 433–9PubMedCrossRef

95.

Coulter D. COX-2 use in New Zealand: a problem of age and death [abstract]. Proc Aust Soc Clin Exp Pharmacol Toxicol 2003; 10: 110

96.

Clarke A, Shakir SAW. Evidence of safety used to support decisions to withdraw medicinal products from the UK and US markets: a literature review. Pharmacoepidemiol Drug Saf 2003; 12Suppl. 1: S149–50

97.

Gimeno V, Castellsague J, Varas C, et al. Gastrointestinal and cardiovascular characterization of users of cyclo-oxygenase-2 (COX-2)-specific inhibitors. 1st International Conference on Therapeutic Risk Management and 19th International Conference on Pharmacoepidemiology; 2003 Aug 21-24; Philadelphia (PA). Pharmacoepidemiol Drug Saf 2003; 12Suppl. 1: S43

98.

Howes L, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25(12): 829–35PubMedCrossRef

Titel: Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?
Linking Pharmacology with Pharmacoepidemiology
verfasst von: Dr David W.J. Clark
Deborah Layton
Saad A.W. Shakir
Publikationsdatum: 01.06.2004
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 7/2004
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200427070-00002

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?

Linking Pharmacology with Pharmacoepidemiology

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten